Gemcitabine Kabi 38 mg/ml koncentrát pro infuzní roztok, GEMSOL, 40 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI clinical trials

A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination with Gemcitabine in Patients with Advanced or Metastatic Cancer with a Focus on Ovarian Cancer

This study is testing a new medicine, LY2880070, alone or with another cancer drug, gemcitabine. It's for women with advanced or metastatic cancer, especially ovarian cancer. We want to see how safe the new medicine is and if it helps control the cancer.